| Epilepsy |
Ending the pain of children with severe epilepsy? An audit of the impact of medical cannabis in 10 patients
|
Zafar, Schlag, Nutt |
2020 |
| Syqe inhaler |
The Syqe Inhaler delivered precise and low THC doses to produce a dose-dependent analgesic effect in patients with neuropathic pain/complex-regional pain syndrome.
|
Almog et al. |
2020 |
| Syqe inhaler |
Pain intensity, 30–60 minutes following inhalations, was reported to be significantly lower than pre-inhalation. The use of the Syqe Inhaler during hospitalisation yielded high levels of patients and staff satisfaction with no complications. |
Vulfons et al. |
2020 |
| Fibromyalgia |
Adjunctive cannabis therapy offers a possible clinical advantage in fibromyalgia patients, especially in those with sleep dysfunctions. The clinical improvement inversely correlated with patient BMI. |
Giorgi et al |
2020 |
| Drug-resistant epilepsy |
All patients reported a reduction in seizure frequency and severity, and some reported improved mood, sleep quality, and general well-being without major side effects. Only one patient experienced one adverse event of mild intensity. |
Pane et al. |
2020 |
| False memory |
Cannabis consistently increases susceptibility to false memories. The results have implications for police, legal professionals, and policymakers with regard to the treatment of cannabis-intoxicated witnesses and suspects and the validity of their statements. |
Kloft et al. |
2020 |
| Fibromyalgia |
Cannabis varieties containing THC caused a significant increase in pressure pain threshold relative to placebo. CBD inhalation increased THC plasma concentrations but diminished THC-induced analgesic effects, indicative of synergistic pharmacokinetic, but antagonistic pharmacodynamic interactions of THC and CBD. |
Van de Donk et al. |
2019 |
| Brain function |
THC disrupts the brain region involved in the subjective experience of THC intoxication. CBD restores the disruption caused by THC, which may explain the potential of CBD to treat disorders such as psychosis and addiction. |
Wall et al. |
2019 |
| Chronic diseases |
Cannabis oil extract may be therapeutically effective and safe for the symptomatic treatment of some chronic diseases – in particular pain. |
Palmieri et al. |
2019 |
| Neurotransmitter function |
THC elicits subjective and cognitive alterations via increased striatal dopaminergic activity and loss of corticostriatal connectivity, which is associated with an increase in striatal glutamate. |
Mason et al. |
2019 |
| Traffic safety |
The point in time after cannabis consumption seems to play an important role concerning driving safety: significantly more driving faults were committed directly after consumption. Three hours after consumption, no significant increase of driving faults was seen. |
Tank et al. |
2019 |
| Chronic pain |
Cannabis therapy, as an addition to traditional analgesic therapy, can be an efficacious tool to make more effective the management of chronic pain and its consequences on the functional and psychological dimensions. |
Poli et al. |
2018 |
| Cannabis use data |
Cannabis use among Dutch patients was analyzed based on prescription data obtained from the Dutch Foundation for Pharmaceutical Statistics. The results showed that an increasing number of Dutch patients are using medicinal cannabis on prescription, while the average daily consumption has remained stable over many years. This suggests the absence of tolerance or cannabis abuse in this population. |
De Hoop et al. |
2018 |
| Brain’s reward circuit |
Public advertising of alcohol or cannabis use elicits striatal activation in the brain’s reward circuit. Reduction of marketing would reduce brain exposure to reward cues that motivate substance use. |
de Sousa et al. |
2017 |
| Gilles de la Tourette |
Cannabis may be effective in treatment-resistant TS patients with vocal blocking tics. |
Jakubovski et al. |
2017 |
| Taste perception |
Administration of cannabis preparations at the low doses tested does not affect sweet taste intensity perception and liking, nor does it influence food preferences in humans. |
De Bruijn et al. |
2017 |
| Non-responders to Nabiximols |
Bedrocan was well tolerated and patients reported no psychoactive effects. Alternative treatment with Bedrocan accounts for a promising response rate in Nabiximols (Sativex) non-responders. |
Sacca et al. |
2016 |
| Adolescents vs adults |
Adolescents felt less ‘stoned’ and reported fewer psychotomimetic symptoms than adults. Adults, but not adolescents, were more anxious and less alert during the cannabis use session. |
Mokrysz et al. |
2016 |
| Decision-making and reward learning |
Cannabis acutely induced a transient amotivational state and CBD influenced the effects of THC on expected value. |
Lawn et al. |
2016 |
| Cannabis and alcohol |
Alcohol facilitated feelings of aggression whereas cannabis diminished aggressive feelings in heavy alcohol and regular cannabis users. |
De Sousa et al. |
2016 |
| Cannabis and cocaine |
Interference of cannabis and cocaine with cognitive impulse control and functional corticostriatal connectivity depends on a specific genotype. |
Ramaekers et al. |
2016 |
| Neurocognitive function |
Executive function, impulse control, attention, psychomotor function and subjective intoxication were significantly worse after cannabis administration relative to placebo. |
Ramaekers et al. |
2016 |
| Cannabis and cocaine |
Cannabis and cocaine demonstrated opposing effects on the early and late phases of error monitoring. |
Spronk et al. |
2016 |
| Human cognition |
The research aimed at exploring how cannabis affects creative thinking, awareness of errors, and the neurotransmitter dopamine among regular cannabis users. It was discovered that cannabis does not improve creativity and that it can decrease error awareness and impair dopaminergic functioning. |
Kowal et al. |
2016 |
| Verbal memory |
Acetylcholine plays an important role in cannabis-induced memory impairment, whereas similar results for glutamate were not observed. |
Theunissen et al. |
2015 |
| Psychedelic symptoms |
Cannabis increased dissociation and psychedelic state, as well as fatigue, confusion, depression and anxiety, and decreased arousal, positive mood, vigor, friendliness, and elation. A broad association between trait impulsivity and psychedelic subjective drug experience appears to be absent. |
Van Wel et al. |
2015 |
| Reversal learning |
Acute effects of cocaine and cannabis on reversal learning as a function of COMTand DRD2 genotype. |
Spronk et al. |
2015 |
| Subjective effects |
Cannabis containing high percentages of THC had a strong effect on the rating of subjective effects. |
Hunault et al. |
2014 |
| Syqe inhaler |
This trial suggests the potential use of the Syqe Inhaler device as a smokeless delivery system of medicinal cannabis, producing a THC pharmacokinetic profile with low inter-individual variation, and achieving pharmaceutical standards for inhaled drugs. |
Eisenberg et al. |
2014 |
| Driving skills |
Cannabis smoking, even at low THC blood concentrations, decreases psychomotor skills and alters the activity of the brain networks involved in cognition. |
Battistella et al. |
2013 |
| Cannabinoid concentrations |
THC, and also THC-A, shows a sharp, high concentration peak just after smoking, with a rapid decrease in these levels within 3 hours. |
Fabritius et al. |
2013 |
| Psychomotor function |
Single doses of cannabis impaired psychomotor function and increased response errors during impulsivity tasks in heavy cannabis users. |
Van Wel et al. |
2013 |
| Heavy vs occasional users |
Heavy cannabis users develop tolerance to some of the impairing behavioral effects of cannabis. |
Theunissen et al. |
2012 |
| THC and alcohol |
Heavy cannabis users develop tolerance to the impairing effects of THC on neurocognitive task performance. Yet, heavy cannabis users did not develop cross-tolerance to the impairing effects of alcohol, and the presence of the latter even selectively potentiated THC effects on measures of divided attention. |
Ramaekers et al. |
2011 |
| Doping by athletes |
In addition to THC-COOH, the pharmacologically active THC and THC-OH should be used as target analytes for doping urine analysis. In the case of light cannabis use, this may allow the estimation of more recent consumption, probably influencing performance during competitions. |
Brenneisen et al. |
2010 |
| Heavy vs occasional users |
THC significantly impaired performance of occasional cannabis users on critical tracking, divided attention and the stop signal task. THC did not affect the performance of heavy cannabis users except in the stop signal task, i.e. stop reaction time increased, particularly at high THC concentrations. |
Ramaekers et al. |
2009 |
| Pharmacokinetics of THC |
The linear association between THC dose and THC serum concentration also applies for high THC doses. |
Hunault et al. |
2008 |
| Pharmacokinetics of irinotecan and docetaxel |
Coadministration of medicinal cannabis, as herbal tea, in cancer patients treated with irinotecan or docetaxel does not significantly influence the plasma pharmacokinetics of these drugs. |
Engels et al. & De Jong et al. |
2007 |
| Pharmacokinetics of THC |
Smoking cannabis with higher THC contents was associated with a dose-related increase of the serum concentrations of THC, physical effects, and psychomotor effects. |
Mensinga et al. |
2006 |
| Motor control |
High potency marijuana consistently impaired executive function and motor control.
|
Ramaekers et al. |
2006 |
| Driving skills |
Serum THC concentrations between 2 and 5 ng/ml establish the lower and upper range of a THC limit for impairment. |
Ramaekers et al. |
2006 |
